Study type
Dermatology and skin studies recruiting now
Skin studies test treatments for conditions such as psoriasis, eczema, acne, alopecia, vitiligo and hidradenitis suppurativa, from creams to tablets and injections.
146 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
More recruiting studies (pay not posted)
- RecruitingPhase 3
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
Pfizer
- Location
- Bryant, AR + 11 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 2/Phase 3
Phase 2/3 Efficacy and Safety of PP405 in Adult Males
Pelage Pharmaceuticals, Inc.
- Location
- Birmingham, AL + 26 other US sites
- Eligibility basics
- Ages 18–55 · Men only
- RecruitingPhase 3
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics
- Location
- Phoenix, AZ + 18 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
Pfizer
- Location
- Birmingham, AL + 28 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
AbbVie
- Location
- Fountain Valley, CA + 29 other US sites
- Eligibility basics
- Ages 12–63
- RecruitingPhase 2
A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)
Spyre Therapeutics, Inc.
- Location
- Indianapolis, IN + 6 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Sanofi
- Location
- Scottsdale, AZ + 19 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS
Novartis Pharmaceuticals
- Location
- Mayfield Heights, OH
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
Sanofi
- Location
- La Jolla, CA + 17 other US sites
- Eligibility basics
- Ages 18–90
- RecruitingPhase 3
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
Pfizer
- Location
- Irvine, CA + 18 other US sites
- Eligibility basics
- Ages 6–14
- RecruitingPhase 3
Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa
Paradigm Therapeutics
- Location
- Rancho Santa Margarita, CA + 3 other US sites
- Eligibility basics
- Ages 1 mo–12
- RecruitingPhase 2
A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)
Novartis Pharmaceuticals
- Location
- El Paso, TX
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
Pfizer
- Location
- Northridge, CA + 7 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 1
Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa
Corvus Pharmaceuticals, Inc.
- Location
- Bowling Green, KY + 8 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Takeda
- Location
- Chandler, AZ + 45 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
Sanofi
- Location
- Phoenix, AZ + 16 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
Sanofi
- Location
- Palo Alto, CA + 14 other US sites
- Eligibility basics
- Ages 6 mo–17
- RecruitingPhase 1
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
Novartis Pharmaceuticals
- Location
- Loma Linda, CA + 10 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
Pfizer
- Location
- Birmingham, AL + 6 other US sites
- Eligibility basics
- Ages 2–11
- RecruitingPhase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Bristol-Myers Squibb
- Location
- Phoenix, AZ + 90 other US sites
- Eligibility basics
- Ages 40+
- RecruitingPhase 2
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
Pfizer
- Location
- Phoenix, AZ + 13 other US sites
- Eligibility basics
- Ages 18–64
- RecruitingPhase 2
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Novartis Pharmaceuticals
- Location
- Birmingham, AL + 23 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 3
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
Novartis Pharmaceuticals
- Location
- Birmingham, AL + 20 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingPhase 3
A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
Novartis Pharmaceuticals
- Location
- Miami, FL + 7 other US sites
- Eligibility basics
- Ages 18+
Who these studies look for
Most require an active, diagnosed skin condition of a certain severity and a pause on some current treatments before starting.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.
Questions
Do I need a diagnosis to join a skin study?
Usually yes, and the site will confirm it at screening. Some studies also recruit people without the condition as a comparison group.